Basic fibroblast growth factor (bFGF) stimulates the proliferation of many cells and it is found in a wide variety of normal or transformed tissues. As demonstrated here, bFGF is also present in cultured human Ewing's sarcoma cells. Unexpectedly, however, bFGF isolated from these cells inhibits their own proliferation, indicating that bFGF can act as an endogenous (autocrine) growth inhibitor for cultured Ewing's sarcoma cells. Since bFGF also inhibits the proliferation of some further tumor cells, but stimulates that of others, it can be considered a bifunctional regulator of tumor cell proliferation. The autocrine growth-inhibitory effect of bFGF in Ewing's sarcoma cells may explain the low mitotic activity of Ewing's sarcomas.
Introduction
Tumor cells, unlike their nontransformed counterparts, can proliferate in the presence of little or no exogenous growth factors. This is probably due to their ability to produce, as well as to respond to, their own growth factors (1) . One of the growth factors thought to act in this manner is basic fibroblast growth factor (bFGF),' a peptide mitogen of Mr of 16,500, which stimulates the proliferation of a wide variety of normal or transformed cells (2). In fact, bFGF is synthesized in and can stimulate the proliferation of cells derived from human embryonal rhabdomyosarcoma (3), a small cell childhood tumor (4, 5) . We therefore wished to determine whether a 1. Abbreviations used in this paper: aFGF, acidic fibroblast growth factor; BCE, brain-derived capillary endothelial; bFGF, basic fibroblast growth factor; DMEM, Dulbecco's modified Eagle's medium; FGF, fibroblast growth factor. similar mechanism might exist in cells derived from other small cell childhood tumors, such as Ewing's sarcomas.
Methods
Cell culture. Stock cultures of SK-ES 1 cells were maintained in gelatinized 10-cm tissue culture dishes containing 10 ml ofculture medium, i.e., Dulbecco's modified Eagle's medium (DMEM) supplemented with calf serum (10%) and antibiotics (6, 7) . All other cell lines were maintained as indicated in the legend to Table I. Cell proliferation assays. Cells were seeded at the indicated densities into 35-mm dishes containing 2 ml oftheir respective medium and every other day received either 10 Al aliquots of samples to be tested or no additions. After various times, the cells were dissociated and counted with a particle counter (Coulter Electronics Inc., Hialeah, FL) (8).
Purification of SK-ES1 cell-derived bFGF. SK-ES 1 cells were grown to confluence in gelatinized 530-cm2 tissue culture dishes (Nunc, Roskilde, Denmark) containing culture medium (6, 7) . Cells (1.8 X 109) were trypsinized, washed twice with ice-cold phosphatebuffered saline (PBS)/0.0 1% bovine serum albumin (BSA), resuspended in 10 mM Tris-HCl (pH 7.0)/2 M NaCl, and sonicated for 2 min at 4°C. The pH was adjusted to 4.5; the cell lysate was incubated for 1 h at 4°C and then centrifuged (15 min, 4C, 50,000 g). The supernatant, diluted sixfold with distilled water, was adjusted with HC1 to pH 7.0 and run on a heparin-Sepharose column (1.2 X 1.3 cm) preequilibrated with 10 mM Tris-HCl buffer (pH 7.0) containing 0.6 M NaCl (9). Aliquots of the fractions eluted with the same buffer containing 0.6, 1.0, 2.0 M NaCl (9-11) were examined for their abilities to stimulate the proliferation ofbrain-derived capillary endothelial (BCE) cells as previously described (8). All ofthe bioactivity was eluted with 2.0 M NaCl, resulting in a 3,000-fold purification of the crude extract. The bioactive fractions were pooled and stored at -70°C.
Preparation ofanti-bFGF antibodies. Rabbits were repeatedly injected (12) with pituitary-derived bFGF (9). The antiserum obtained from one rabbit (Ede) was purified by protein A-Sepharose affinity chromatography (13), and the IgG fractions containing the anti-bFGF antibodies were stored at -70°C. The anti-bFGF antibodies, but not control antibodies, are able to inhibit bFGF-induced but not acidic fibroblast growth factor (aFGF)-induced proliferation of capillary endothelial cells (14) . They do not cross-react with aFGF or unrelated peptides like insulin, transferrin, epidermal growth factor, thyroglobulin, and cytochrome c in a radioimmunoassay using '25I-bFGF as the ligand (14) .
Binding of I25I-labeled bFGF to SK-ESJ cells. SK-ES1 cells and '25I-labeled bFGF ('251-bFGF) (15) were incubated with or without unlabeled compounds in 24-well 
Results
Ewing's sarcoma, a most common tumor of adolescents, develops primarily in the pelvis and femur (4) . Like embryonal rhabdomyosarcoma, it belongs to the so-called small cell childhood tumors (4, 5) . Although its histogenesis is still a matter of controversy, a vascular endothelial cell origin has been proposed (5) . In view of our recent demonstration that bFGF can act as a self-stimulating (autocrine) growth factor for vascular endothelial (14) or embryonal rhabdomyosarcoma (3) cells, it was of interest to determine whether a similar mechanism might exist in Ewing's sarcoma cells.
To examine this possibility, we used the human SK-ES1 Ewing's sarcoma cell line (6, 7) that, under the conditions employed (see legend to Fig. 1 ), adhered tightly to the tissue culture dishes. Extracts prepared from SK-ES 1 cells were subjected to heparin-Sepharose affinity chromatography, a method suitable for the rapid and selective purification of bFGF (9-1 1), and the fractions eluted were then examined for their abilities to stimulate the proliferation of bFGF-dependent target cells (3, 8, 9) . In fact, the SK-ESl cell extract con- Fig. 1 ). This chromatographic behaviour is indistinguishable from that of bFGF (9-1 1), suggesting that the partially purified cell extract that eluted with 2.0 M NaCl contained bFGF.
This possibility was examined by a fibroblast growth factor (FGF) radioreceptor binding assay using BHK-21 cell membranes (15) . Although this assay is less sensitive than FGF bioassays, it allows the specific and precise determination of FGF (15) . Indeed, the partially purified cell extract, like native bFGF, inhibited the binding of 251I-bFGF to the FGF receptor (Fig. 1 A) . Furthermore, like bFGF, it stimulated the proliferation of capillary endothelial cells (Fig. 1 B) . (14), a closely related mitogen (1 1, 17) . Indeed, the inhibition of SK-ES I cell proliferation by the partially purified SK-ES1 cell extract was completely blocked by anti-bFGF antibodies, but not by control antibodies (Fig. 1 C) . In the absence of the partially purified SK-ES1 cell extract, the control antibodies had no influence on cell proliferation, whereas the anti-bFGF antibodies induced an increase in cell densities (Fig. 1 C) . These results indicate that bFGF is present in the partially purified SK-ES1 cell extract, that it is responsible for the inhibition of SK-ES 1 cell proliferation, and, further, that bFGF can act as an endogenous growth inhibitor for SK-ES 1 Ewing's sarcoma cells. These results were substantiated by the demonstration that native pituitary-derived bFGF (9) also inhibited SK-ES1 cell proliferation (Fig. 2 A) . The inhibition was maximal at bFGF concentrations (about 0.5 ng/ml) that are known to induce maximal growth stimulation in other bFGF target cells (2). Surprisingly, it declined to control values at bFGF concentrations above 10 ng/ml. The structurally and functionally related aFGF also inhibited SK-ES1 cell proliferation, but its concentrations required were about 500-fold higher than those of bFGF (Fig. 2 A) . The structural specificity ofgrowth inhibition was confirmed by the demonstration that other peptides, like epidermal growth factor, insulin, transferrin or the fibronectin fragment Gly-Arg-Gly-Asp-Ser-Pro-Lys (at concentrations ranging from 0.5 to 500 ng/ml) had no effect on SK-ES1 cell proliferation (data not shown).
The bFGF-induced inhibition of SK-ES 1 cell proliferation is reversible. When fresh medium or anti-bFGF antibodies were added to SK-ES1 cells that had been exposed to bFGF, either treatment, but not treatment with control antibodies, reversed the bFGF-induced inhibition of cell proliferation (Figs. 2 B and C) the control antibodies had no effect on cell proliferation, whereas the anti-bFGF antibodies induced a slight increase in cell proliferation (Fig. 2 C) . Thus, the bFGF-induced inhibition of SK-ES1 cell proliferation is a reversible process and does not represent simple cytotoxicity. bFGF also inhibited the proliferation of other tumor cell lines derived from Ewing's sarcoma, angiosarcoma, or osteosarcoma (Table I) . However, bFGF did not inhibit, or did even stimulate, the proliferation of various other tumor cells (Table  I) . Thus, the bFGF-induced inhibition of cell proliferation is a cell-specific process.
Since (Fig. 3 A) . Scatchard analysis of the binding interaction (Fig. 3 A, inset) revealed the presence of about 14,000 FGF receptors/SK-ES cell with an apparent dissociation constant of 76 pM, indicating no gross alteration of FGF receptor numbers or dissociation constant, as compared with other cell species, in which bFGF acts as a growth stimulator (15, 21, 22 (Fig. 3 B) . Thus, SK-ES1 cells bear specific FGF receptors on their surface, to which their endogenous bFGF can bind and whereupon it probably exerts its inhibitory effect.
Discussion
We have demonstrated here that bFGF is present in cultured human Ewing's sarcoma cells, and that the endogenous bFGF can bind to FGF receptors on their surface and then inhibit cell proliferation. Inhibition is blocked by anti-bFGF antibodies, which do not cross-react with aFGF (14) , whereas the (3, 14) . This agrees with our observation that bFGF gene transcripts could not be detected (data not shown) by conventional Northern blot analyses (3, 14) . However, a considerable amount of the intracellular bFGF might be released in vivo to exert its growth-inhibitory effect. This might occur upon cell leakage, e.g., in the frequently observed necrotic tumor areas, a feature highly characteristic for Ewing's sarcoma. In fact, the absence of necrosis mitigates against the diagnosis of Ewing's sarcoma (23 5) , partially purified SK-ES1 cell extract (1.5 Ag/ml) (lane 2), pituitary-derived bFGF (50 or 100 ng/ml) (lanes 3 and 4, respectively), control antibodies (12 ,g/ml) (lane 6), or anti-bFGF antibodies (6 jg/ml) (lane 7). Cells were then washed twice with PBS and cell surface-bound ligands were cross-linked using disuccinimidyl suberate (0.2 mM) (15, 21) . Cells were lysed and radioactivity in the lysate was analyzed by
